Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.

Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.

The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.

Inclusion Criteria:

• Patients aged 70 years and older
• Patients referred for a assessment of a newly diagnosed multiple myeloma
• Patients for who the initial therapy proposed is either melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a phase 3 trial.
• Patients who provide informed written consent

Exclusion Criteria:

• Patients who refuse the study
• Patients who won't have therapy
• Patients can't respond to geriatric assessment because of severe cognitive disorder
• Patients with a legal guardian